Regenerative medicine company Novadip Biosciences revealed on Tuesday the election of Jeff Abbey as its chief executive officer.
Effective early 2019, Abbey will succeed the outgoing Jean-Francois Pollet.
Since 2002, Abbey has worked with Argos Therapeutics Inc, an immuno-oncology cell therapy company, in multiple positions including president and chief executive officer for the past eight years.
The company's lead programme is an autologous three-dimensional cell therapy that has completed enrolment of a phase I/IIa trial in spinal fusion patients. Its second clinical programme is currently enrolling patients with non-healing bone fractures.
Medivir and Vetbiolix report positive results from VBX-1000 Proof-of-Concept clinical study
Norgine submits first marketing authorisation application submissions for approval of eflornithine
Innovent Biologics names new Oncology CMO
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
Precision Epigenomics partners with TruDiagnostic
Portage Biotech expands evaluation of strategic alternatives
Stamford Pharmaceuticals starts locally advanced basal cell carcinoma (laBCC) trial of SP-002
QST selects RayStation for advanced carbon ion therapy
Candel Therapeutics granted FDA Orphan Drug Designation for CAN-2409 in pancreatic cancer treatment
ELIAS Animal Health names new chief revenue officer
Innate Pharma reports preclinical efficacy of IPH45
Roche attains CE Mark for first companion diagnostic for HER2-low metastatic breast cancer
BioCity Biopharma's BC2027 Phase one study IND application receives US FDA approval
enGene Holdings names new senior vice president, Urologic Oncology and Clinical Development